Endpoint Clinical

Executive Summary

Endpoint Clinical is a privately held provider of Randomization and Trial Supply Management (RTSM) software, serving the clinical trial industry since 2009. Its platform, used at over 90,000 clinical trial sites worldwide, offers customizable solutions that improve operational efficiency and reliability for sponsors and CROs. As a specialized player in the growing digital health and AI/ML space, Endpoint Clinical is well-positioned to benefit from the increasing complexity of clinical trials and the demand for decentralized trial technologies. However, as a private company with limited public information, its growth trajectory and competitive positioning are challenging to assess without disclosed financials or recent milestones. The company's focus on RTSM, a niche but critical component of trial logistics, suggests steady demand, but scalability and differentiation against larger players remain key considerations.

Upcoming Catalysts (preview)

• Q3 2026Strategic partnership with a major CRO or pharmaceutical company40% success
• Q4 2026Launch of AI-enhanced RTSM platform with predictive supply management30% success
• Q1 2027Expansion into decentralized clinical trial (DCT) capabilities50% success